187669-62-1

Basic information

• Product Name: 1-(4-Trifluoromethoxyphenyl)piperazine
• Synonyms: 1-(4-Trifluoromethoxyphenyl)piperazine;4-(4-Trifluoromethoxyphenyl)piperazine
• CAS NO: 187669-62-1
• Molecular Formula: C₁₁H₁₃F₃N₂O
• Molecular Weight: 246.23
• Product Categories: pharmacetical
• Mol File: 187669-62-1.mol

Chemical Properties

• Boiling Point: 308.5°Cat760mmHg
• Flash Point: 140.4°C
• Appearance: /
• Density: 1.242g/cm³
• Vapor Pressure: 0.000677mmHg at 25°C
• Refractive Index: 1.486
• CAS DataBase Reference: 1-(4-Trifluoromethoxyphenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Trifluoromethoxyphenyl)piperazine(187669-62-1)
• EPA Substance Registry System: 1-(4-Trifluoromethoxyphenyl)piperazine(187669-62-1)

Safety Data

• Hazardous Substances Data: 187669-62-1(Hazardous Substances Data)

Usage

Uses

Used in Recreational Drug Use:
TFMPP is used as a recreational drug for its psychoactive effects, which include mild stimulation, euphoria, and slight hallucinogenic properties. However, its use has been associated with adverse effects and potential for abuse, resulting in its ban in many countries.
Used in Herbal Smoking Blends:
TFMPP has been used as an ingredient in herbal smoking blends, where it is marketed as a legal alternative to MDMA. Despite its psychoactive effects, the substance has been linked to harmful side effects and is now banned in many countries due to its potential for abuse and harm.

InChI:InChI=1/C11H13F3N2O/c12-11(13,14)17-10-3-1-9(2-4-10)16-7-5-15-6-8-16/h1-4,15H,5-8H2

Upstream product

• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 110-85-0 piperazine 
• 461-82-5 4-(trifluoromethoxy)aniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 490030-45-0 tert-butyl 4-(4-(trifluoromethyl)-phenyl)-piperazine-1-carboxylate 
• 490030-46-1 1-(4-(trifluoromethoxy)phenyl)piperazine hydrochloride 

Downstream Products

• 681032-13-3 (S)-1-(2-chloro-4-nitroimidazol-1-yl)-2-methyl-3-[4-(4-trifluoromethoxyphenyl)piperazin-1-yl]propan-2-ol 
• 1231170-13-0 1-(2,2-dimethyl-[1,3]dioxan-5-ylmethyl)-4-(4-trifluoromethoxyphenyl)piperazine 
• 1083075-52-8 carbamic acid 1-phenyl-3-[4-(4-trifluoromethoxy-phenyl)-piperazin-1-yl]-propyl ester 
• 1369891-55-3 C₂₀H₂₃F₃N₂O₂ 
• 1369892-10-3 C₂₀H₂₁F₃N₂O₂ 
• 1394867-94-7 2-{3-(4-chlorobenzoyl)-5-phenyl-4-[(4-(4-(trifluoromethoxy)phenyl)piperazin-1-yl)methyl]thiophen-2-yl}isoindoline-1,3-dione 
• 1394868-06-4 2-{3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-4-[(4-(4-(trifluoromethoxy)phenyl)piperazin-1-yl)methyl]thiophen-2-yl}isoindoline-1,3-dione 
• 1334718-24-9 7-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperazin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1334718-23-8 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperazin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426520-98-0 C₁₈H₂₀F₃N₃O 

Relevant articles and documents

Nitroimidazole compound as well as preparation method and application thereof

The invention discloses a novel nitroimidazole compound as well as a preparation method and application thereof. The nitroimidazole compound has a general formula (I) shown in the specification.

Heteroaromatic acetamide derivative, preparation and applications thereof

The present invention provides a heteroaromatic acetamide derivative, a preparation and applications thereof, wherein the derivative comprises a pharmaceutically acceptable salt and/or a solvate thereof. According to the present invention, the experiment results prove that the heteroaromatic acetamide derivative can specifically bind to transient receptor potential ankyrin 1 (TRPA1) and inhibit orreduce the activity of TRPA1, and can be used for treating diseases mediated by TRPA1; and the inhibitor of the present invention further comprises a pharmaceutical composition of the compound, and amethods for preparing the compounds. The derivative has a general formula defined in the specification.

Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands

Two series of hybrid analogues were designed, synthesized, and evaluated as a novel class of selective ligands for the dopamine D3 receptor. Binding affinities of target compounds were determined (using the method of radioligand binding assay). Compared to comparator agent BP897, compounds 2a and 2c were found to demonstrate a considerable binding affinity and selectivity for D3 receptor, and especially compound 2h was similarly potent and more selective D3R ligand than BP897, a positive reference. Thus, they may provide valuable information for the discovery and development of highly potent dopamine D3 receptor ligands with outstanding selectivity.

Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors

The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION

Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.

5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS

The present invention discloses 5-[3-[piperazin-l-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives according to Formula (I), wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS 4 and 5 for the prophylaxis or treatment of inflammatory diseases or diseases involving degradation of cartilage or disruption of cartilage homeostasis, such as e.g. osteoarthritis.

Chrysin-piperazine conjugates as antioxidant and anticancer agents

Synthesis of 7-(4-bromobutoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one intermediate treating chrysin with 1,4-dibromobutane facilitated combination of chrysin with a wide range of piperazine moieties which were equipped via reacting the corresponding amines with bis(2-chloroethyl)amine hydrochloride in diethylene glycol monomethyl ether solvent. Free radical scavenging potential of prepared products was analyzed in vitro adopting DPPH and ABTS bioassay in addition to the evaluation of in vitro anticancer efficacies against cervical cancer cell lines (HeLa and CaSki) and an ovarian cancer cell line SK-OV-3 using SRB assay. Bearable toxicity of 7a-w was examined employing Madin-Darby canine kidney (MDCK) cell line. In addition, cytotoxic nature of the presented compounds was inspected utilizing Human bone marrow derived mesenchymal stem cells (hBM-MSCs). Overall, 7a-w indicated remarkable antioxidant power in scavenging DPPH+ and ABTS++, particularly analogs 7f, 7j, 7k, 7l, 7n, 7q, 7v, 7w have shown promising free radical scavenging activity. Analogs 7j and 7o are identified to be highly active candidates against HeLa and CaSki cell lines, whereas 7h and 7l along with 7j proved to be very sensitive towards ovarian cancer cell line SKOV-3. None of the newly prepared scaffolds showed cytotoxic nature toward hBM-MSCs cells. From the structure-activity point of view, nature and position of the electron withdrawing and electron donating functional groups on the piperazine core may contribute to the anticipated antioxidant and anticancer action. Different spectroscopic techniques (FT-IR, 1H NMR, 13C NMR, Mass) and elemental analysis (CHN) were utilized to confirm the desired structure of final compounds.

Practical method for parallel synthesis of diversely substituted 1-phenylpiperazines

A simple and practical method to prepare 'libraries' of substituted 1-phenylpiperazine building blocks in parallel format has been developed.

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF

The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.